Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease — Stella

Home/Parkinson's Disease/Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

View on ClinicalTrials.gov

Recruiting

Back to Parkinson's Disease trials

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Zhongnan hospital, Wuhan, Hubei

Key details

Phase

Post-approval study

Sponsor

YangPan

Collaborators

Eisai China Inc., Nanjing University

Enrollment target

~44 participants

Started

March 2026

Primary completion

December 2026

Age range

50 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.